AlloSure can offer peace-of-mind and provide physicians with information to help guide pediatric patients’ post-transplant care.²˒³
What is AlloSure?
AlloSure Heart is a donor-derived cell-free DNA (dd-cfDNA) test for noninvasive transplant surveillance, providing a direct measure of allograft injury in pediatric heart transplant patients. AlloSure Heart is a donor-derived cell-free DNA (dd-cfDNA) test for noninvasive transplant surveillance, providing a direct measure of allograft injury in pediatric heart transplant patients.
Increasing levels of dd-cfDNA serve as a leading indicator of graft injury.
AlloSure is a reliable indicator of rejection in pediatric patients of all ages¹
Robust data including a study1 exclusively focused on pediatric patients <15 years establishes AlloSure Heart as a non-invasive method of rejection detection.
AlloSure Heart helps reduce pediatric surveillance biopsies and increase biopsy yield
AlloSure Heart assessment in place of protocol EMB reduced surveillance biopsies by 81% in a pediatric cohort with no short-term adverse outcomes.²
CareDx Partners with leading Healthcare Professionals at Adult and Pediatric Heart Transplant Centers Across the U.S.
Clinical evidence demonstrates AlloSure Heart for Pediatrics supports effective heart transplant rejection surveillance while reducing reliance on invasive monitoring approaches.²
Resources
Incorporating AlloSure Heart into your workflow
How to Order AlloSure
Find the steps needed to place an order, with ordering options that fit your center.
Interpretation Guides
Access practical guidance for understanding and interpreting results.
Downloads
Webinars
Events
Connect with our team to learn more about AlloSure Heart for Pediatrics
Internal Data on File. Publication pending.
Feingold et al. Pediatr Transplant. 2022;26(1):e14124. doi:10.1111/petr.14124.